INTRODUCTION {#SEC1}
============

The MDS1 and EVI1 complex locus (*MECOM*) encodes two isoform subgroups through the induction of alternate transcription start sites preceding either MDS1 or EVI1 loci ([@B1]). Either the *MECOM*-encompassing PRDM3 isoforms or the MDS1-lacking EVI1 isoforms can be produced, with additional isoforms arising from alternative splicing events. PRDM3 belongs to the PRDM family of transcription factors characterized by an N-terminal PR-SET domain, followed by an array of C2H2 zinc finger motifs, while EVI1 possesses the zinc fingers but is N-terminally truncated and lacks the PR-SET domain (ΔPR). PRDM16 (also known as MEL1) is a closely related paralog of PRDM3 sharing 53% sequence identity with the N-terminus of PRDM3, which can also be omitted through expression of the ΔPR PRDM16 isoform ([@B2]).

*MECOM* and *PRDM16* gene expression has been observed across many tissue types and both are implicated in haematopoietic development ([@B3],[@B4]). The PRDM3 isoform is critical for maintaining long-term hematopoietic stem cell function, while the EVI1 isoform has an essential role in hematopoiesis. However, *MECOM* expression declines after hematopoiesis ([@B5]). PRDM16 is preferentially expressed by haematopoietic and neuronal stem cells and functions to attenuate reactive oxygen species-related stress through the promotion of hepatocyte growth factor gene expression ([@B6],[@B7]). Additionally, PRDM16 is a key determinant of brown adipose tissue identity by suppressing genes of white adipose tissue, while independently activating genes for brown adipose tissue ([@B8]). Proteins that drive key developmental pathways are frequently dysregulated in cancer and thus it is no surprise that both PRDM3 and PRDM16 are directly linked to various aspects of oncogenic transformation.

A Yin-Yang analogy describes the isoform imbalance observed with some PRDM proteins that either function as tumor suppressors or oncogenes depending on the retention of the PR-SET domain ([@B11]). For example, EVI1 is a potent oncogene associated with transformation and proliferation in multiple leukemias, while expression of PRDM3 is frequently abrogated and a low PRDM3/EVI1 expression ratio predicts an extremely poor prognosis for acute myeloid leukemia (AML) patients ([@B1],[@B12]). Additionally, in solid tumors from ovarian and hepatocellular carcinomas, EVI1 overexpression has been shown to drive oncogenesis and progression, while EVI1 in colon cancer was shown to be critical for metastasis ([@B16]). Aberrant *MECOM* isoform expression can arise from 3q26 genomic rearrangements imparting an imbalance between EVI1 and PRDM3 isoforms and with it, poor patient survival in AML ([@B15],[@B19]). Rearrangements may arise from retroviral insertions between the MDS1 and EVI1 loci, which interrupt normal PRDM3 transcription and lead to EVI1 overexpression ([@B12]). Some leukemia patients lack an altered 3q26 karyotype and instead overexpress the EVI1 isoform through activation by mixed-lineage leukemia (MLL) chimeric genes MLL-ENL or MLL-AF9 ([@B22]). *PRDM16* is similar to the *MECOM* gene, wherein lentiviral-induced genomic alterations lead to depletion of full-length PRDM16 and higher levels of the N-terminally truncated ΔPR PRDM16 isoform, while full-length PRDM16 may also function as a tumor suppressor protein in leukemias ([@B2],[@B21],[@B23]). Together, these consistent pathologies, along with the high sequence conservation between the PRDM3 and PRDM16 proteins, appear to suggest that an exclusive molecular property of both full-length isoforms can function to repress certain aspects of tumor formation and/or progression.

The N-terminal PR-SET domain belongs to a distinct class of SET domains that are sometimes described for a lack of intrinsic lysine methyltransferase (KMT) activity. Reported KMT activity for PRDM3 and PRDM16 PR-SET domains includes weak mono-methyltransferase activity on lysine 9 of histone H3 (H3K9me1), which occurs in the cytosol ([@B26]). Additionally, PRDM16 has been reported to methylate lysine 9 and lysine 4 on histone H3 in separate studies ([@B25],[@B27]). Interestingly, a key catalytic tyrosine residue present in the robustly active KMT enzyme PRDM9, as well as in all other demonstrably enzymatic SET domains, is absent from PRDM3 and PRDM16, suggesting a potential alternative function of these N-terminal domains ([@B28],[@B29]). The C-terminal zinc finger motifs of PRDM3 and PRDM16 cluster into two separate domains and facilitate specific interactions with DNA. In PRDM3, the N-terminal zinc fingers bind a GATA-like motif and the C-terminal zinc fingers bind to an ETS-like motif ([@B30],[@B31]). ChIP-seq analysis of EVI1-binding sites in SKOV3 ovarian carcinoma cells demonstrated enrichment at myeloid leukemia genes ([@B32]), while an analysis across a panel of AML cell lines found that EVI1 binding leads to deregulation of genes involved in apoptosis, differentiation and proliferation ([@B33]). Interestingly, while PRDM16 can localize to the same DNA-binding sites as PRDM3/EVI1 through its zinc finger domains, ChIP-seq analysis suggests that PRDM16 can be recruited indirectly to chromatin in brown adipose tissue via interactions with DNA-binding partners, including C/EBPβ and PPARγ, rather than by direct binding to DNA ([@B10],[@B23]). Both PRDM3 and PRDM16 bind to C-terminal binding protein (CtBP) through canonical PLDLS CtBP-binding sites located between the two zinc finger clusters, which can promote cellular growth by repressing transcription downstream of transforming growth factor-β signaling ([@B34],[@B35]). Additionally, the EVI1 isoform has been reported to form homo-oligomers capable of enhanced CtBP binding ([@B36]). While it is well established that the zinc finger motifs direct genomic localization, it remains unclear if the N-terminal amino acids that are exclusive to full-length PRDM3 and PRDM16 contribute to biologically relevant protein--protein interactions.

The NuRD chromatin remodeling complex is an essential epigenetic regulator of developmental genes. In haematopoietic stem cells, NuRD regulates the expression of genetic pathways critical for proliferation and differentiation, while perturbation of NuRD signaling is associated with cancer and premature aging ([@B37]). The NuRD complex possesses adenosine triphosphate-dependent chromatin-remodeling and histone deacetylase activities conferred by CHD3 and CHD4 (chromodomain/helicase/DNA-binding) proteins and HDAC1 and HDAC2 (histone deacetylase) proteins, respectively ([@B38]). Structural studies suggest that the core NuRD complex contains the HDAC1 and HDAC2 proteins, the MTA1 and MTA2 (metastasis-associated) proteins, as well as the RBBP4 and RBBP7 proteins ([@B38],[@B39]). Additional complex members include the CHD3 and CHD4 proteins, the MBD2 and MBD3 (methyl-CpG-binding domain) proteins and the GATAD2A and GATAD2B (GATA Zinc Finger Domain Containing) proteins ([@B38]). The NuRD complex is composed of multiple RBBP4/7 subunits, which scaffold between histone H3 tails and MTA1/2 subunits. ([@B38]). Several transcription factors are known to bind RBBP4/7 in the NuRD complex by competing for the histone H3 binding interface, including SALL1, FOG1, PHF6 and BCL11A ([@B41]). Interestingly, FOG1 forms a strong interaction with RBBP4 and has a secondary interaction with the MTA proteins within the NuRD complex ([@B42],[@B45]). A previous immunoprecipitation with mass spectrometry (IP-MS) screen of EVI1 interactions has identified the NuRD complex members RBBP4, HDAC1, HDAC2 and CHD4 as potential interactors ([@B46]). Additionally, a yeast two-hybrid screen found that EVI1 interacts with the MBD3b protein ([@B47]), but this interaction was not observed in IP-MS assay ([@B46]). It remains unclear how EVI1 interacts with the NuRD complex and whether the N-terminal residues of PRDM3 contribute to these interactions.

In this study, we find that the RNA expression profiles of *MECOM* transcripts across a panel of solid tumors support the Yin-Yang hypothesis of a cancer-specific imbalance of full-length PRDM3 and the ΔPR isoform known as EVI1. Using proteomics IP-MS experiments to compare the interactomes of the full-length and ΔPR isoforms of PRDM3 and PRDM16, we determine that NuRD complex members are significantly enriched for both full-length proteins compared to the ΔPR counterparts. Through biophysical characterization and cellular co-localization analysis, we identify an interaction between the N-terminal residues of full-length PRDM3 and PRDM16 with RBBP4 and present the crystal structures of PRDM3 and PRDM16 peptides (residues 1--12) bound to RBBP4 perpendicular to the electronegative β-propeller axis typically occupied by the histone H3 tail. Together, these data provide a molecular and structural framework for understanding how full-length PRDM3 and PRDM16 may regulate epigenetic machinery which is lost in some cancers.

MATERIALS AND METHODS {#SEC2}
=====================

Gene and isoform expression analysis {#SEC2-1}
------------------------------------

The Cancer Genome Atlas (TCGA) datasets for *MECOM* transcript expressions were obtained from the FireBrowse resource (<http://firebrowse.org/>), for all patients with matched healthy and tumor tissue samples ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). *MECOM* gene expression was estimated from the summation of RSEM normalized counts for each transcript and statistical significance was calculated with the R programming language (version 3.2) ([@B48]). *MECOM* transcript expression levels from healthy and tumor samples from TCGA studies where *MECOM* expression was significantly decreased was used to perform a principal component analysis (PCA) using the 'prcom' function in the R environment.

Co-Immunoprecipitation and mass spectroscopy {#SEC2-2}
--------------------------------------------

T47D cells were transfected with GFP-tagged, murine Prdm3 or Prdm16 plasmids using Turbofect following manufacturer's recommendations. Forty eight hours after transfection, cells were washed with ice-cold phosphate buffered saline (PBS), and lysed in high-salt buffer (10 mM Tris--HCl, pH 7.9, 420 mM NaCl, 0.1% NP-40), followed by three freeze--thaw cycles. After lysates were cleared by centrifugation (13 000 rpm for 20 min at 4°C), 5% of the lysates were saved for western blot input controls and 80% was used for the IP procedures.

For the immunoprecipitation step, the lysates were incubated with 5 μg of anti-GFP antibody (Invitrogen) overnight at 4°C. Magnetic protein A/G beads (Dynabeads, Life technologies), were mixed at 1:1 ratio (10 μl of each per sample) and washed with low salt AFC buffer twice (10 mM Tris--HCl, pH 7.9, 100 mM NaCl, 0.1% NP-40). The beads were incubated 4 h at 4°C with the lysate/antibody mix and washed twice in low-salt AFC. The beads were washed a 3rd time in low-salt AFC in the absence of NP-4 and eluted in 0.5 M ammonium hydroxide, before flash freezing in liquid nitrogen.

For the MS procedure, samples were dried in a Speedvac concentrator (Eppendorf) and reconstituted in 44 μl of 50 mM NH4HCO3 and 1 μl of 100 mM tris(2-carboxyethyl)phosphine, pH 7.5 (TCEP-HCl). Samples were incubated at 37°C for 1 h with shaking and cooled down to room temperature before adding 1 μl 500 mM iodoacetamide. Samples were incubated in the dark at room temperature for 45 min, then digested using 1 μg Trypsin (Promega) with overnight incubation at 37°C, and the reaction was stopped with 2 μl of acetic acid. Samples were desalted using Zip-Tips (Millipore) following the manufacturer's instructions and processed for MS using an Orbitrap Velos mass spectrometer (Thermo Fisher Scientific).

co-IP validation experiment and western blot {#SEC2-3}
--------------------------------------------

For co-IP experiment on transfected T74D cells, cell lysis and immunoprecipitation were performed as described in the IP-MS experiment, except for the third wash and elution. The beads were washed a third time in low salt AFC, resuspended in 30 μl of Laemmli buffer and boiled for 5 min. The whole 30 μl were processed for western blot using antibodies for GFP (Living Colors JL-8, Clontech), RBBP4 (R&D systems, MAB7416-SP), MTA1 (CST, 5647) and HDAC2 (CST, 5113). Endogenous co-IP experiments were performed on T47D and MCF7 cells using the same methodology as described above, using 5 μg of RBBP4 antibody (Abcam, ab79416) for the IP and blotted with PRDM3/EVI1antibody (ab124934).

Mass Spectrometry analysis {#SEC2-4}
--------------------------

SAINTexpress (v3.6.1) ([@B49]) was used to calculate the probability that identified proteins from the Immunoprecipitation and mass spectroscopy experiments were significantly enriched above background contaminants by comparing the expected and observed peptide counts between the GFP-tagged prey proteins and the GFP-only negative control (*n* = 3). Prey proteins with a calculated Bayesian false discovery rate of ≤1% where called as high confidence protein--protein interactions ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) and sorted by odds ratio for each bait--prey interaction with the full-length and ΔPR isoforms.

Cellular co-localization analysis {#SEC2-5}
---------------------------------

Full-length mouse Prdm3 complementary DNA (cDNA) (National Center for Biotechnology Information (NCBI) accession number NM_001361034) or a truncated mutant lacking the first twelve amino-acids were amplified by polymerase chain reaction (PCR) and cloned into the AgeI site of the mCherry-LacR-NLS-KpnI plasmid (Luijsterburg *et al.*, 2012) to generate a C-terminally fused mCherry-LacR-NLS tag onto Prdm3. Full-length human RBBP4 cDNA (NCBI accession number NM_005610) was amplified by PCR and cloned into pDONR221 vector with Gateway BP Clonase II mix and then transferred into the pCDNA6.2/N-EmGFP-DEST vector with Gateway LR Clonase II mix (ThermoFisher Scientific). Constructs encoding an N-terminal mCherry-LacR-NLS tag onto Prdm3 were cloned into the KpnI site of the same vector. All constructs were verified by sequencing.

U-2 OS cells expressing 256 repeats of a LacO array (U-2 OS LacO Cells, previously described ([@B50])) were cultured in DMEM media (Thermo Fisher Scientific, cat. \#31966021) supplemented with 10% fetal bovine serum (v/v, Biosera, cat. \#FB-1001/500) and antibiotics (1% Pencillin Streptomycin (Thermo Fisher Scientific, cat. \#15070063), 1 μg/ml puromycin (Thermo Fisher Scientific, cat. \#A1113803) at 37°C and 10% CO~2~.

U-2 OS LacO cells were washed with PBS, trypsinized using 0.25% trypsin-ethylenediaminetetraacetic acid(Thermo Fisher Scientific, cat. \#25200056) for 3 min at room temperature and seeded in 24-well cell culture dishes (30 000 cells in 1 ml media per well). After incubating for 20 h at 37°C and 10% CO~2~, cells were transfected with plasmids using the FuGENE6 reagent (Promega, cat \#E2311) according to the manufacturer's instructions (100 ng per plasmid in 20 μl OptiMem (Thermo Fisher Scientific, cat. \#31985070) with 1 μl FuGENE6 per well), then incubated for 24 h at 37°C and 10% CO~2~. Transfected cells were then washed with PBS, trypsinized and re-plated onto 8-well glass imaging chamber dishes (Thermo Fisher Scientific, cat. \#155411PK) in 300 μl media. Cells were incubated for 20--24 h at 37°C and 5% CO~2~ before fixing.

Cells were washed with PBS twice before fixing at room temperature with 4% formaldehyde (300 μl in PBS) for 10 min, then washed twice with PBS, and were subsequently incubated with 0.2% Triton-X100 (300 μl in PBS) for 5 min at room temperature. Cells were washed with PBS three times, then incubated with a 4′,6-diamidino-2-phenylindole (DAPI) solution (300 μl of 1 μg/ml from a 1 mg/ml stock; Thermo Fisher Scientific, cat. \#62248) for 2 min at room temperature. Cells were washed twice with PBS, and then glycerol buffer (300 μl, 90% glycerol, 10% 20 mM Tris--HCl pH 8.0) was added to the cells. Cells were stored at room temperature, away from light and were imaged within one week of fixing.

Cells were imaged using a Zeiss LSM 710 scan-head (Zeiss GmbH, Jena, Germany) coupled to an inverted Zeiss Axio Observer Z1 microscope equipped with a high-numerical-aperture (N. A. 1.40) 63 × oil immersion objective (Zeiss GmbH, Jena, Germany). A 488 nm excitation laser and a 494--542 nm emission filter were used to detect GFP fluorescence. A 594 nm excitation laser and a 598--700 nm emission filter were used to detect mCherry fluorescence. Quantification was carried out using the ImageJ software. Co-localization enrichment was calculated using the following formula: $$\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}\begin{equation*}{\rm Enrichment}(\% ) = \frac{{\frac{{GFP_{{\rm Intensity}}^{{\rm foci}}}}{{GFP_{{\rm Area}}^{{\rm foci}}}} - \frac{{\left( {GFP_{{\rm Intensity}}^{{ {\rm Nucleus}}} - GFP_{{\rm Intensity}}^{{\rm foci}}} \right)}}{{\left( {GFP_{{\rm Area}}^{{\rm Nucleus}} - GFP_{{\rm area}}^{{\rm foci}}} \right)}}}}{{max\left( {GF{P_{{\rm Intensity}}}} \right)}} \times 100\end{equation*}\end{document}$$

Protein expression and purification {#SEC2-6}
-----------------------------------

Full-length human RBBP4 (residues 1--425) was cloned into the baculovirus expression vector pFBOH-LIC (GenBank [EF456740](EF456740)) encoding an N-terminal His~6~ tag and a tobacco etch virus protease cleavage site. The protein was expressed in Sf9 cells infected with baculovirus using the Bac-to-Bac expression methodology (Invitrogen). The harvested cells were lysed by rotation in lysis buffer containing 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 300 mM NaCl, 5% glycerol, 0.3% NP-40, protease inhibitor cocktail (Roche) and 1000 U of benzonase, followed by centrifugation. The clarified lysate was loaded onto cobalt resin equilibrated with lysis buffer and incubated for 1.5 h with agitation at 4°C. The beads were washed with 50 column volumes of 50 mM Hepes pH 7.5, 300 mM NaCl, 5% glycerol, 10 mM Imidazole. The bound protein was eluted using 50 mM Hepes pH 7.5, 300 mM NaCl, 5% glycerol, 300 mM Imidazole. To cleave the His-tag, eluted protein was dialyzed into dialysis buffer (50 mM Hepes pH 7.5, 300 mM NaCl, 5% glycerol, 2 mM CaCl) with 500 U of Thrombin overnight at 4°C with agitation. The cleaved protein was purified by ion exchange chromatography using a Source S column with an AKTA Explorer (GE Healthcare) and a linear, buffered salt gradient between Buffer A: 20 mM Hepes, 2.5% glycerol and buffer B: 20 mM Hepes, 2.5% glycerol, 1 M NaCl. Fully homogeneous protein was dialyzed back into dialysis buffer.

Structural determination {#SEC2-7}
------------------------

Cleaved RBBP4 protein was concentrated to 10.0 mg/ml and combined in a 1:1.2 molar ratio with synthetic human PRDM3 or PRDM16 peptide (1--12; Genscript) at 4°C. The complex was crystallized from sitting drops by vapor diffusion from a 1:1 mixture of protein solution and crystallization buffer (20% \[PRDM3\] or 22% \[PRDM16\] PEG3350, 0.2 M sodium malonate pH 7, 0.1 M BisTris pH 6). Protein crystals were cryoprotected in well solution containing 33% glycerol in mother liquor. Detraction data for RBBP4:PRDM3 were collected at 100 K using a Rigaku FR-E Superbright rotating anode home source with a Rigaku SATURN A200 detector at a wavelength of 1.54178 Å, while data for RBBP4:PRDM16 were collected at 100 K from a synchrotron source at the Advanced Photon Source from beamline 24-ID-E with an ADSC QUANTUM 315 detector at a wavelength of 0.92819 Å. All data were processed and scaled with XDS ([@B51]) and Aimless ([@B52]). Initial phases were estimated by molecular replacement using PhaserMR ([@B53]) from a known structure of RBBP4 (PDB 4r7a). The structural models were refined using REFMAC5 ([@B54]) and manually checked with COOT ([@B55]). Each asymmetric unit of the crystals contained two binary peptide:RBBP4 complexes with global identical quaternary architecture. The highly similar PRDM3:RBBP4 and PRDM16:RBBP4 asymmetric units superimposed with a root mean square deviation (r.m.s.d.) of 0.13 Å over 696 Cα atoms, while the PRDM3:RBBP4 and PRDM16:RBBP4 biological assemblies superimposed to the paired, non-crystallographic symmetry mate with r.m.s.d. values of 0.16 and 0.18 Å, respectively. The full β-propeller structure of RBBP4 encompassing all seven WD40 repeats and the N-terminal α-helix were modeled into the electron density, but like other deposited structures, residues 1--3, 89--112, 356--359 and 411--425 could not be modeled due to inadequate electron density at these predicted disordered positions. Electrostatic surface potentials were calculated using the Adaptive Poisson-Boltzmann Solver (APBS) plug-in in PyMOL ([@B56]). Images were generated using PyMOL (The PyMOL Molecular Graphics System, v1.7.4, Schrödinger, LLC.).

Isothermal titration calorimetry (ITC) {#SEC2-8}
--------------------------------------

For isothermal titration calorimetry (ITC) measurements of full-length human RBBP4 (residues 1--425) interactions with PRDM3 and PRDM16 peptides ([@B1]) and histone H3 peptides ([@B1]), RBBP4 was dialyzed into a buffer containing 20 mM Hepes, 150 mM NaCl and 2.5% glycerol. Peptides were suspended in the same buffer to a final concentration of 0.50 mM. A preliminary peptide injection of 0.06 μl was followed by subsequent 2-μl injections into the sample cell containing 167 μl of 50 μm RBBP4. The reported *K*~D~ and *n* values are based on the average from three experiments and are accompanied by the standard deviation of the measurements. The data were acquired on a Nano ITC from TA Instruments at 25°C and fitted with an independent-binding site model using NanoAnalyze software (v3.7.0).

*In silico* alanine scan {#SEC2-9}
------------------------

Calculation of the changes in theoretical binding free energy upon alanine mutation of each residue of the PRDM3 peptide bound to RBBP4 (pdb: 6bw3) was carried out using ICM-Pro (Molsoft) ([@B57]). Briefly, the protein complex was processed to repair missing sidechains and add hydrogens followed by energy minimization to relieve possible atomic clashes. ΔGibbs free energy of binding was calculated for the wild-type PRDM3 peptide and all 10 alanine scan mutants. ΔΔGibbs free energy of binding was determined by ΔG(Mut)-ΔG(WT).

RESULTS {#SEC3}
=======

PRDM3 is encoded by the MECOM gene and is depleted in solid tumors {#SEC3-1}
------------------------------------------------------------------

Altered *MECOM* gene expression is commonly associated with initiation and aggressiveness in a variety of hematologic cancers ([@B15]). To assess if *MECOM* expression perturbations are common in other cancer types, we examined *MECOM* gene expression using RNA-seq data obtained from TCGA from a variety of solid tumor types. *MECOM* gene expression was defined as the total transcripts detected from any part of the *MECOM* locus. First, total *MECOM* gene expression was compared between autologous healthy and tumor tissue samples from a variety of cancer studies that possessed \>10 matched sample pairs (Figure [1A](#F1){ref-type="fig"} and [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Pairwise comparisons between autologous samples revealed statistically significant decreases in *MECOM* expression in renal (KIRC and KIRP), lung (LUSC and LUAD), prostate (PRAD) and breast (BRCA) carcinomas, as well as increased *MECOM* expression in liver (LIHC) and thyroid (THCA) carcinomas, as compared to matched healthy tissue (Figure [1A](#F1){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

![Full-length PRDM3 depletion is prevalent in *MECOM*-deficient solid tumors. (**A**) *MECOM* gene expression analysis in TCGA studies for patient-matched healthy (yellow) and tumor (blue) tissue samples. See [Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"} for details. (\*\*\* *q*-value \<10^--9^, \*\* *q*-value \<10^--4^, \* *q*-value \<10^--3^, Wilcoxon rank-sum test, Bonferroni correction) (**B**) Protein domain diagram of *MECOM* transcripts, which contain the PR-SET domain (referred to as PRDM3 in green) or lack it (referred to as MDS1 in purple and EVI1 in *orange*). Note: uc003ffn.3, uc011bpk.1 and uc003ffi.3 encode an identical amino acid sequence and were grouped as uc003ffn.3\*. (**C**) Principle component analysis of *MECOM* isoform expression levels from RNA-seq data comparing patient-matched healthy and tumor tissue samples. (**D**) Principle Component 2 (PC2) loading values of each *MECOM* isoform. Color coding of the ten protein-encoding transcripts correspond to (B), while uc003ffo.1 is a non-coding transcript, shown in gray.](gky1192fig1){#F1}

To examine the underlying features of altered *MECOM* gene expression, we compared the expression of each individual transcripts arising from the *MECOM* locus, across healthy tissue and tumor tissue samples. A total of 10 protein-encoding *MECOM* transcripts are annotated in the TCGA data (Figure [1B](#F1){ref-type="fig"}). The full-length PRDM3-coding transcript (uc011bpj.1) encodes a protein that possesses an N-terminal PR-SET domain followed by two Zinc finger (ZnF) arrays. Two shorter PRDM3-coding transcripts (uc010hwn.2 and uc003ffl.2) encode intact PR-SET domains, but harbor deletions in the C-terminal half of the protein. The six EVI1-coding transcripts lack the PR-SET domain (ΔPR) but retain some or all of the ZnF arrays. One transcript derived from the MDS1 loci (uc011bpl.1) encodes a short protein truncated in the middle of the PR-SET domain and an additional non-coding transcript (uc003ffo.1) brings the total number of *MECOM*-gene derived transcripts to 11. PCA was used to examine the expression of the 11 *MECOM* transcripts, contrasting healthy and tumor tissues from the TCGA studies that had a significant decrease in *MECOM* gene expression. The set of all 11 *MECOM* transcript expression levels for each patient's tumor and normal tissue were used to compute principal component (PC) values. The PC1 and PC2 values were plotted to explore any potential clustering of the tumor and healthy tissue samples. Interestingly, PC2 distinguished between the majority of healthy and tumor tissue samples, wherein the majority of healthy tissue samples were primarily located along the negative PC2 axis, while most tumor samples localized on the positive axis (Figure [1C](#F1){ref-type="fig"}). To assess which *MECOM* transcripts accounted for the distinction between healthy and tumor samples within PC2, we examined the PC loading plot, which indicated that the expression of full-length PRDM3 (uc011bpj.1) was the largest contributor for samples appearing along the negative PC2 axis (Figure [1D](#F1){ref-type="fig"}). Taken together, these findings suggest that expression of the full-length PRDM3 transcript is a major contributor to distinguish healthy from tumor tissue in renal, lung, prostate and breast carcinomas.

N-termini of Prdm3 and Prdm16 interact with the NuRD complex {#SEC3-2}
------------------------------------------------------------

Despite evidence for the tumor suppressive properties of full-length PRDM3 compared to the N-terminal truncated oncogenic EVI1, the function of the N-terminus remains unclear. Full-length PRDM3 and its closely related paralog PRDM16 possess an ∼80 residue unstructured region preceding the PR-SET domain, which are both absent in the N-terminally truncated isoforms (referred to as ΔPR). Although the PR-SET domains of PRDM3 and PRDM16 have been associated with weak, exonuclear KMT activity in the cytoplasm ([@B26]), a role in mediating protein--protein interactions has not been described. To investigate the potential role of this region, we performed IP-MS assays using full-length mouse Prdm3 and Prdm16 proteins and their respective ΔPR isoforms (Figure [2A](#F2){ref-type="fig"}). C-terminally tagged GFP-fusion constructs of the full-length and ΔPR isoforms were individually expressed in T47D ductal carcinoma cells and high-affinity prey proteins were purified after with a stringent, high-salt immunoprecipitation protocol and then identified by mass spectrometry.

![The N-termini of full-length PRDM3 and PRDM16 isoforms function as protein--protein interaction scaffolds. (**A**) Protein domain diagram of full-length (left) and ΔPR (right) PRDM3 and PRDM16 isoforms used for co-immunoprecipitation with mass spectrometry. (**B** and **C**) Prey proteins associated with PRDM3 (B) and PRDM16 (C) by co-immunoprecipitation with the full-length (left) and ΔPR (right) bait. Prey proteins scoring with a BFDR ≤ 1% are ranked by decreasing Odds ratio relative to GFP control co-immunoprecipitation. Prey proteins shared between full-length and ΔPR isoforms are indicated by color and peptide count relative to GFP control is indicated by size. NuRD complex members are outlined.](gky1192fig2){#F2}

Gene ontologies were obtained from the lists of high confidence protein--protein interactions using the DAVID software (version 6.8), to identify enriched ontologies related to 'cellular components', and terms passing a Benjamini FDR cut-off of \< 0.001 were compared. As expected, all the bait--prey interactions were enriched for terms associated with nuclear localization, while both the ΔPR isoforms of Prdm3 and Prdm16 were also associated with exonuclear ontology terms such as 'cytosol' and 'extracellular exosome' ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Interestingly, only the full-length isoforms were enriched for 'NuRD complex', in agreement with our IP-MS data ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Indeed, we examined the highest ranked bait--prey interactions of the full-length and ΔPR isoforms or Prdm3 and Prdm16 and found that the NuRD complex members were the most confident interactions with the full-length isoforms, while only RBBP4 and CHD4 were pulled down by the ΔPR isoforms (Figure [2B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}).

To compare NuRD complex member associations between the full-length and ΔPR isoforms, we plotted the spectral count fold-change over that of the GFP-control immunoprecipitation for Prdm3 and Prdm16 (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). A 4-fold peptide enrichment was observed for full-length over ΔPR isoforms, for significantly called NuRD complex members common to both full-length and ΔPR isoforms (e.g. RBBP4), while most NuRD complex members detected for the full-length isoforms fell bellow the significance threshold or were undetected for the ΔPR bait proteins (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). We performed co-immunoprecipitation with western blot analysis to directly contrast the interaction between full-length and ΔPR Prdm3 and Prdm16 isoforms with members of the core NuRD complex. Western blot analysis confirmed that the full-length Prdm3 and Prdm16 isoforms associated with RBBP4, MTA1 and HDAC2, while associations with the ΔPR isoforms were not detected (Figure [3C](#F3){ref-type="fig"}). To further validate this interaction for the endogenous human proteins, we preformed reciprocal co-immunoprecipitations in high EVI1 expressing T47D cells and high PRDM3 expressing MCF7 cells. Western blot analysis after the co-immunoprecipitation of endogenous RBBP4 demonstrated that endogenous, human PRDM3 protein associated with RBBP4, while EVI1 was not detected ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). These findings indicate that the N-terminal region of full-length PRDM3 and PRDM16 are key mediators of the NuRD complex interaction.

![The NuRD complex members are enriched interactors with full-length PRDM3 and PRDM16. (**A** and **B**) Spectral count fold change above control (log2) of the NuRD complex members that co-immunoprecipitated with (A) PRDM3 and (B) PRDM16 comparing ful-length (*x*-axis) and ΔPR (*y*-axis) bait. (**C**) Immunoblotting of specific NuRD complex members following co-immunoprecipitation with full-length and ΔPR isoforms of PRDM3 and PRDM16. Ten percent protein input is shown in the right-hand panel. GFP empty vector was used as a control (Ctrl). Blots shown are representative of three experiments.](gky1192fig3){#F3}

N-termini of PRDM3 and PRDM16 bind directly to RBBP4 {#SEC3-3}
----------------------------------------------------

We hypothesized that the residues that facilitated the interaction with NuRD would be conserved between PRDM3 and PRDM16. As expected the PR-SET domains are highly conserved among both the mouse and human proteins, as are two short sequence regions N-terminal to the PR-SET domains ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). Interestingly, the first 12 residues of both proteins also share close sequence identity with the N-terminal residues of histone H3 ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}), which has been shown to interact with the RBBP4 *Drosophila* paralog Nurf55 ([@B40]). To assess the potential role of the 12 aa peptide regions versus the PR domains for NuRD complex interactions, we purified proteins comprised of the first ∼200 residues of human PRDM3 and PRDM16 with and without these 12 residues and performed *in vitro* pull-down assays with purified recombinant RBBP4, which had the highest likelihood of interaction calculated by SAINTexpress for both full-length PRDM3 and PRDM16 among all the bait--prey interactions in our IP-MS datasets (Figure [3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}). Recombinant RBBP4 only associated with the first ∼200 N-terminal residues of PRDM3 and PRDM16 *in vitro* when the first 12 amino acids were also present ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}).

We next preformed peptide-binding assays by ITC to assess the interaction between residues 1--12 of human PRDM3 and PRDM16 with full-length RBBP4. Equilibrium dissociation constants (*K*~D~) with a 1:1 binding ratio between peptide and RBBP4 were calculated to be 2.96 ± 0.34 μM and 3.15 ± 0.36 μM for PRDM3 and PRDM16 peptides, respectively (Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}). By comparison, a histone H3 peptide (residues 1--25) bound to human RBBP4 with a *K*~D~ of 1.50 ± 0.38 μM (Figure [4C](#F4){ref-type="fig"}). Examination of the crystal structure of a histone H3 peptide with Nurf55, suggested that lysine 4 of H3 (H3K4) is important for RBBP4 interactions ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). As a control for peptide binding to RBBP4, we tested the affinity of a 25-residue histone H3 peptide bearing a trimethylated lysine 4 (H3K4me3) and observed that the *K*~D~ decreased by 10-fold relative to the unmodified peptide ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). This suggested that the lysine conserved among histone H3, PRDM3 and PRDM16 may be an important contributor to the interaction.

![The first 12 residues of PRDM3/16 interact with RBBP4. (**A--C**) *In vitro* measurement of dissociation constant (*K*~D~) and molar stoichiometry (*N*) of (A) PRDM3, (B) PRDM16 and (C) Histone H3 peptides with RBBP4 measured by ITC (experiment performed in triplicate, standard deviation is shown). (**D**) Cellular interaction between PRDM3 and RBBP4 measured by LacO/LacR chromatin immobilization assay. PRDM3-mCherry-LacR-NLS with WT PRDM3 or PRDM3 lacking the 12 N-terminal residues (ΔN12) were assessed for co-localization with GFP-RBBP4. (**E**) Quantification of the PRDM3 (WT or ΔN12) co-localization with RBBP4 shown in (D). The violin plots represent the GFP intensity increase over background in the mCherry foci, calculated from *n* = 100 cells.](gky1192fig4){#F4}

To investigate the importance of the 12 N-terminal residues of the full-length isoforms in a cellular context, we assessed co-localization of PRDM3 with RBBP4 by employing a LacO/LacR chromatin immobilization assay. U2OS cells with a stably integrated 256 LacO array were transfected with C-terminally tagged PRDM3-mCherry-LacR-NLS with either wild-type (WT) PRDM3 or PRDM3 lacking the 12 N-terminal residues (PRDM3^ΔN12^) to assess for co-localization with co-expressed GFP-RBBP4. PRDM3-LacR fusion proteins localized at the LacO array as single red foci (Figure [4D](#F4){ref-type="fig"} and [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). GFP-RBBP4 colocalized in clear foci with WT PRDM3-LacR, but not with PRDM3^ΔN12^ or the control (Figure [4D](#F4){ref-type="fig"}). When co-expressed with PRDM3^ΔN12^, GFP-RBBP4 produced a diffuse GFP signal in both the nucleus and the cytoplasm. In some cells, weak GFP foci could be spotted slightly above background GFP fluorescence in the PRDM3^ΔN12^-expressing cells, as well as in N-terminally tagged PRDM3^ΔN12^-expressing cells ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Quantification of the GFP signal increase at the mCherry foci normalized to the background nuclear GFP fluorescence showed a significant increase in signal intensity with WT and mutant PRDM3 proteins (*P* \< 10^−16^, ANOVA/Dunnett analysis; Figure [4E](#F4){ref-type="fig"}). Taken together with the immunoprecipitation and affinity pull-down assays, these results show that the 12 N-terminal residues of full-length PRDM3 and PRDM16 are essential for the interaction with RBBP4 in a cellular environment.

Co-crystal structure of RBBP4 with PRDM3/PRDM16 N-terminal peptide {#SEC3-4}
------------------------------------------------------------------

RBBP4 helps direct the NuRD complex onto chromatin via associations with the histone H3 tail, but transcription factors can also serve as an intermediary between the NuRD complex and chromatin by competing for occupancy at the histone H3 interface on RBBP4 ([@B40],[@B42]). To examine the structural basis of the interaction between PRDM3 and PRDM16 with RBBP4, we determined the crystal structures of full-length RBBP4 (residues 1--425) bound to human PRDM3 and PRDM16 peptides (residues 1--12) at 2.2 and 2.0 Å, respectively (Figure [5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}; Table [1](#tbl1){ref-type="table"}). The nearly identical structures of the PRDM3 and PRDM16 peptides bound to RBBP4 revealed that both peptides bind to the electronegative histone H3-binding interface of RBBP4 in an extended conformation (Figure [5](#F5){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

![Crystal structure of RBBP4 in complex with the PRDM3 (1--12 amino acid) peptide. (**A**) Stick representation of PRDM3 ([@B1]) peptide \[Oxygen atoms (red) and nitrogen (blue)\] bound to the ribbon representation of RBBP4. (**B**) Electrostatic surface potential representation of the binding pocket with aligned PRDM3 peptide. RBBP4 surface color indicates electrostatic potential ranging from −7kT/e (red) to +7kT/e (blue). Electrostatic surface potentials were calculated using the APBS.](gky1192fig5){#F5}

###### 

Data for X-ray Crystal Structure of PRDM3/16 (1--12aa) with RBBP4.

  PDB structure            6bw3                       6bw4
  ------------------------ -------------------------- ---------------------------
  Contents                 RBBP4 and PRDM3(1--12aa)   RBBP4 and PRDM16(1--12aa)
  **Data collection**                                 
  Space group              P 1 2~1~ 1                 P 1 2~1~ 1
  wavelength (Å)           1.54178                    0.97918
    *a, b, c* (Å)          75.98,59.82,101.77         76.03,59.86,101.84
    *α, β, γ* (°)          90, 94.55, 90              90, 94.55, 90
   Resolution (Å)          46.95-2.2 (2.27-2.2)       19.78-2.0 (2.05-2.0)
   *R*~merge~ (%)          0.1 (0.1)                  0.06 (0.7)
   *I/σ*(*I*)              2.44                       2.75
   Completeness (%)        99.4                       99.2
   Redundancy              4.1 (4.0)                  3.9 (4.1)
  **Refinement**                                      
   Resolution (Å)          46.95 - 2.2                19.78 - 2.0
   Reflections             44 059                     58 442
   *R*~work~/*R*~free~     0.215/0.246                0.199/0.233
  Wilson B factor (Å^2^)   34.0                       34.8
  Protein atoms            5841                       5877
  Water molecules          110                        112
  Unidentified molecules   12                         12
   r.m.s.d. values                                    
  Bond length (Å)          0.011                      0.012
  Bond angle (°)           1.48                       0.95
   Ramachandran values                                
  Favored (%)              96.1                       97.2
  Allowed (%)              3.5                        2.5
  Outliers (%)             0.4                        0.3

\*Values in parentheses are for high-resolution shell.

*R*-Factor = Σ *hkl* ‖*F~o~*\|−\|*F~c~*‖/Σ *hkl* \|*F~o~*\|, where *F~o~* and *F~c~* are the observed and calculated structure factor amplitudes for reflection *hkl*.

*R* ~free~ is calculated against a 5% random sampling of the reflections that were removed before structure refinement.

r.m.s.d. = root mean squared deviation.

The peptide:RBBP4 interactions are similar to histone H3 on Nurf55 ([@B40]) and include salt bridges, hydrogen bonds, hydrophobic contacts and cation--π stacking (Figure [6A](#F6){ref-type="fig"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). At the N-terminus, the positively charged amine groups of the Met1 residues of PRDM3 and PRDM16 form salt bridges with Asp248 and Glu231 on RBBP4 (Figure [6B](#F6){ref-type="fig"}). Prominently, the positively charged Arg2 and Lys4 sidechains orient toward the highly electronegative RBBP4 β-propeller axis where the Arg2 guanidinium moiety is sandwiched between the aromatic sidechains of Tyr181 and Phe321 forming stabilizing cation--π interactions, while additionally participating in a salt bridge and hydrogen bond network with Glu231, Arg129, Glu231 and Asn277 (Figure [6B](#F6){ref-type="fig"}). The cationic ϵ-amino group of Lys4 forms salt bridges with Glu179 and Glu126, and hydrogen bonds with Tyr181 and Asn128, with hydrophobic packing of the aliphatic component of the sidechain against the sidechain of Leu45 (Figure [6C](#F6){ref-type="fig"}). As reported from Thr2 of histone H3 on Nurf55 ([@B40]), Ser3 from PRDM3 and PRDM16 is solvent exposed and does not interact with RBBP4 directly. Weak electron density for the Arg6 and Arg8 sidechains was only apparent in some biological assemblies of PRDM3:RBBP4 and PRDM16:RBBP4, suggesting that the salt bridges of Arg6 with Asp74 and Arg8 with Glu75 and Glu42 may not be important contributors to the peptide:RBBP4 interaction (Figure [6D](#F6){ref-type="fig"}). The aliphatic and cationic regions of the Lys9 sidechain form hydrophobic and polar contacts with the aliphatic and anionic regions of the Glu41 sidechain, respectively, as well as a salt bridge with Glu75 (Figure [6E](#F6){ref-type="fig"}). The electron density of Leu10 was inadequate to distinguish the position of its sidechain or the subsequent resides ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}), while the important interactions with RBBP4 occur with residues 1--9 of both peptides. To assess the validity of our structural model, we preformed an *in silico* alanine scan of the PRDM3 peptide and calculated the difference in Gibbs binding energy between the wild-type and mutant peptides ([Supplementary Figure S8A](#sup1){ref-type="supplementary-material"}). The Lys4 sidechain had the largest theoretical contribution to RBBP4 binding and a K4A mutant peptide of PRDM3 ([@B1]) lacked detectable binding to RBBP4 as measured by ITC ([Supplementary Figure S8B](#sup1){ref-type="supplementary-material"}).

![Amino acid interactions at the PRDM3 peptide-RBBP4 interface. (**A**) The interface between PRDM3 ([@B1]) residues (tan) and RBBP4 residues (green). Interactions between PRDM3 centered at (**B**) arginine 2, (**C**) lysine 4, (**D**) arginine 6 and (**E**) lysine 9 are indicated with dashed lines. Interactions within 4 Å (purple) and 3 Å (yellow) are detailed in [Supplementary Table S4](#sup1){ref-type="supplementary-material"}.](gky1192fig6){#F6}

Our structural elucidation of the PRDM3 and PRDM16 peptides bound to RBBP4 revealed a conserved interaction network common to other RBBP4 interacting proteins that binding perpendicular to the β-propeller axis. The N-terminal PRDM3 and PRDM16 peptides share higher sequence identity with the histone H3 peptide than all other peptides from transcription factors known to bind RBBP4 (Figure [7C](#F7){ref-type="fig"}). Sequence and structural alignments of RBBP4-binding peptides at the β-propeller axis clearly demonstrate the importance of the conserved arginine-lysine pair, which makes critical contacts at the highly electronegative groove on RBBP4 (Figure [7A](#F7){ref-type="fig"}--[C](#F7){ref-type="fig"}). Notably, the small and polar Thr3 residue found between the arginine and lysine residues of histone H3 is replaced with a Ser in PRDM3 and PRDM16, while this residue is absent in all other previously identified binding peptides, (Figure [7B](#F7){ref-type="fig"} and [C](#F7){ref-type="fig"}). These small and polar residues do not form direct interactions with RBBP4, but instead extend the peptide backbone to enable consistent sidechain orientation towards RBBP4 (Figure [7B](#F7){ref-type="fig"}). Additionally, an alanine residue is found at position 7 of histone H3 and PRDM3/16, which is a proline in all other structures, further exemplifying the peptide backbone similarity with histone H3 that is exclusive to PRDM3 and PRDM16 (Figure [7C](#F7){ref-type="fig"}).

![PRDM3 and PRDM16 mimic the RBBP4-histone H3 interaction. (**A**) Structure alignment of all reported peptides that bind perpendicular to the RBBP4 β-propeller axis. (**B**) Structure alignment of arginine, threonine/serine and lysine from H3, PRDM3 and PRDM16 (top) and arginine and lysine from FOG1, PHF6, BCL11a and AEBP2 (bottom). (**C**) Sequence alignment of all reported peptides that bind to the RBBP4 top hole. Colors correspond to A and B panels. (**D**) A model illustrating a potential mechanism for how full-length PRDM3 and PRDM16 could tethering the NuRD complex to chromatin and subsequently regulate transcription. Dashed line and arrows indicate potential secondary interactions between MBD3 of NuRD and the first zinc finger motifs of PRDM3 and PRDM16.](gky1192fig7){#F7}

DISCUSSION {#SEC4}
==========

The Yin-Yang paradigm of oncogenesis describes a situation where an imbalance between an oncogene and a tumor suppressor encoded by the same gene gives rise to cancer ([@B11]). The differential expression of short, oncogenic and long, tumor suppressive isoforms has been reported for several PRDM family members, including PRDM1, PRDM2, PRDM3, PRDM5 and PRDM16 ([@B23],[@B58]). It is well established that chromosomal aberrations at the PRDM3-encoding gene, *MECOM*, are found in up to 10% of AML cases with poor survival outcomes ([@B13],[@B14]). The expression levels of specific *MECOM* isoforms suggests that the N-terminal residues of PRDM3 bestow a tumor suppressor function, while the oncogenic shorter EVI1 isoform is overexpressed in myeloid, ovarian, liver and colon tumors, and correlates with poor outcome in AML ([@B1],[@B12],[@B13],[@B15]). Indeed, this is supported by our comparative analysis of *MECOM* isoform expression between patient-matched tumor and healthy tissues and identified a previously unreported loss of full-length PRDM3 expression as a common feature of certain solid tumor types, such as renal, lung, prostate and breast carcinomas.

To further our understanding towards a potential disease mechanism, we searched for unique molecular characteristics of the full-length PRDM3 protein that may explain the Yin-Yang paradigm. We used IP-MS experiments to directly compare the potential protein--protein interactions between the full-length and ΔPR isoforms of the PRDM3 and PRDM16 paralogs and present the molecular basis for a novel protein--protein interaction that is unique to the full-length isoforms. Specifically, the first 10 N-terminal residues of full-length PRDM3 and PRDM16 directly engage the NuRD chromatin remodeling complex via the histone H3 binding interface on RBBP4. We propose a model in which this interaction recruits the NuRD complex to genomic loci specifically bound by the full-length protein isoforms of PRDM3 and PRDM16 (Figure [7D](#F7){ref-type="fig"}).

The full-length PRDM3 and PRDM16 proteins possess an N-terminal ∼80 residue unstructured region followed by the PR-SET domain, which are both absent in the ΔPR isoforms. While the PR-SET domains have been reported to have weak intrinsic KMT activity, reports have been inconsistent in identifying either H3K4 or H3K9 as the substrate in either the nucleus or cytosol ([@B25]). PRDM3 is also known to interact with established KMT enzymes such as G9a and SUV39H1 ([@B62]), which could potentially contribute trace KMT activity to preparations or PRDM3 that contain trace amounts of these robust enzymes. Moreover, both PRDM3 and PRDM16 lack a key catalytic tyrosine residue conserved in all other established SET-domain KMT enzymes ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). Therefore, we hypothesized that there may be an alternative activity attributed to the N-terminal region missing from oncogenic ΔPR isoforms. We focused on potential protein--protein interactions, which could account for molecular functions across the PR-SET domain as well as the preceding unstructured residues in the full-length proteins. Unlike previous studies, our IP-MS experiments are the first to directly compare the potential protein--protein interactions found for the full-length and ΔPR isoforms of the PRDM3 and PRDM16 paralogs. We show that the previously demonstrated interactions between EVI1 and epigenetic factors like the CtBP proteins and the CSNK2A1 and CSNK2B components of the CK2 complex ([@B34],[@B46]) were also found for the full-length PRDM3 protein, as well as both the full-length and ΔPR PRDM16 protein isoforms. Using a yeast two-hybrid screen, Spensberger *et al.* found that EVI1 interacts specifically with the NuRD complex member MBD3b ([@B47]). However, in a subsequent study performed by Bard-Chapeau *et al.*, who used proteomic IP-MS experiments in an ovarian cancer cell line, showed that while RBBP4, HDAC1, HDAC2 and CHD4 were associated with EVl1, MBD3b was not detected ([@B46]). Through our proteomics IP-MS experiments, we found that while both the full-length and ΔPR isoforms of the PRDM3 and PRDM16 proteins associated with some NuRD complex members like RBBP4 and CHD4, only the full-length isoforms were able to pull-down the complete NuRD complex. Furthermore, our co-IP experiments demonstrated that the associations between the ΔPR isoforms and RBBP4 fall below the assay's detection threshold. Additionally, the EVI1 protein has been demonstrated to form homo-oligomers ([@B36]), but it is unclear if EVI1 and PRDM3 can form hetero-oligomers. A hetero-dimerization event could explain how the ΔPR proteins could indirectly associate with the NuRD complex through their longer counterparts, which would justify a weaker relative association with NuRD complex members. Taken together, our proteomics and structural data suggest that the full-length PRDM3 and PRDM16 proteins form a stable complex with NuRD and therefore we hypothesize that the full-length isoforms can direct NuRD to specific genomic loci, while EVI1 and ΔPR PRDM16 likely lack this ability due to a weaker association.

The NuRD chromatin remodeling complex has been implicated in both promotion and suppression of tumorigenesis, growth and metastasis ([@B37],[@B63]). This paradoxical behavior emerges from its ability to epigenetically regulate genes for either tumor suppressors or oncogenic factors depending on specific associations with genomic localization factors. Multiple studies have demonstrated that the NuRD complex can associate with oncogenic transcription factors like BCL11A via RBBP4 in triple-negative breast cancer ([@B44]), TWIST via MTA2 to drive metastasis in carcinomas ([@B64]) and NAB2 via CHD4 in prostate cancers ([@B65]). Additionally, NuRD also associates with tumor suppressing transcription factors like PHF6 ([@B43]) and SALL1 ([@B41]) via RBBP4, as well as c-JUN via MBD3 ([@B66]). RBBP4 and RBBP7 are integral components of the core NuRD complex, serving as a scaffold for the MTA proteins, while functioning as chromatin recognition interfaces through binding to the histone H3 tail. A previous ChIP-seq analysis of CHD4 showed that the NuRD complex localized at genomic loci marked by trimethylated lysine 4 on histone H3 (H3K4me3), which is a post-translational modification incompatible with RBBP4/7 binding ([@B40],[@B67]). Interestingly, BCL11A, PHF6, SALL1 and FOG1 all interact with NuRD by competing for RBBP4/7 at the histone H3-binding interface, thereby demonstrating how NuRD localization can depend on the balance of transcription factors available within specific nuclear environments.

Given that PRDM3 and PRDM16 directly interact with NuRD via RBBP4, it is noteworthy that we did not identify any other RBBP4/7 containing complexes in our IP-MS experiments. The RBBP4 and RBBP7 paralogs share a 90% sequence identity with effectively identical histone H3 binding interfaces. Other RBBP4-binding transcription factors like PHF6 and FOG1 have also been found to exclusively associate with NuRD ([@B42],[@B43]), while alternatively, BCL11A was demonstrated to bind RBBP4 in the NuRD, PRC2, and SIN3A complexes ([@B44]). Structural studies have shown that when RBBP4 is found in PRC2, the histone H3 binding interface is engaged by either AEBP2 or SUZ12. While we observed that a histone H3 peptide binds roughly twice as tightly to RBBP4 than PRDM3 and PRDM16 peptides, competitive binding assays between BCL11A and histone H3 peptides suggest that BCL11A has a three times greater affinity for RBBP4, which may explain why it is capable of binding multiple RBBP4-containing complexes ([@B44]). Furthermore, the potential of multivalent interactions between PRDM3 and PRDM16 with the NURD complex remains unexplored. Studies have shown that the transcription factor FOG1 binds to the MTA proteins and RBBP4 in NuRD ([@B42],[@B45]) and it would be likely that a conserved region between EVI1 and the ΔPR PRDM16 proteins could facilitate this secondary interaction, perhaps on MBD3b. While we did not observe that MBD3 associated with either of the ΔPR proteins, it is interesting that MBD3 deletions have been implicated in cancer progression ([@B68]).

In summary, we have identified an important function of the N-termini of PRDM3 and PRDM16, which bind directly to RBBP4 to facilitate an interaction with the NuRD chromatin remodeling complex. Our data is consistent with a model in which full-length PRDM3 and PRDM16 proteins function as transcriptional co-repressors by directing NuRD to specific genomic loci. The truncation of the N-terminus dramatically decreases the interaction, which warrants further investigation into the resulting transcriptional changes and could suggest a mechanism for the tumor-suppressive properties of full-length PRDMs through their interaction with RBBP4/NuRD.

DATA AVAILABILITY {#SEC5}
=================

Atomic coordinates and structure factors for the reported crystal structures have been deposited with the Protein Data Bank under accession codes 6bw3 and 6bw4.
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======================

###### 

Click here for additional data file.
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